The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model.
about
Molecular Epidemiology of a Vancomycin-Intermediate Heteroresistant Staphylococcus epidermidis Outbreak in a Neonatal Intensive Care Unit.In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infectionTreatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.
P2860
The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
The activity of vancomycin aga ...... n vitro pharmacokinetic model.
@en
The activity of vancomycin aga ...... n vitro pharmacokinetic model.
@nl
type
label
The activity of vancomycin aga ...... n vitro pharmacokinetic model.
@en
The activity of vancomycin aga ...... n vitro pharmacokinetic model.
@nl
prefLabel
The activity of vancomycin aga ...... n vitro pharmacokinetic model.
@en
The activity of vancomycin aga ...... n vitro pharmacokinetic model.
@nl
P2093
P356
P1476
The activity of vancomycin aga ...... n vitro pharmacokinetic model.
@en
P2093
Bennett PM
MacGowan AP
Salisbury V
P304
P356
10.1093/JAC/48.5.727
P407
P577
2001-11-01T00:00:00Z